title: Situating the trovan trial with the use of experimental ebola therapies is like comparing an apple with an orange.
authors: Medical Research Council Unit, Fajara, P.O. Box 273, Banjul, The Gambia, West Africa, mafolabi@mrc.gm.
authors: Muhammed O
authors: MO
authors: Afolabi
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000941:ethics*; D057176:Compassionate Use Trials / Q000941:ethics*; D004196:Disease Outbreaks / Q000517:prevention & control*; D005655:Funeral Rites; D006297:Health Services Accessibility / Q000941:ethics*; D019142:Hemorrhagic Fever, Ebola / Q000453:epidemiology* / Q000517:prevention & control*; D006801:Humans; D011322:Primary Prevention / Q000941:ethics*; D040242:Risk Reduction Behavior
chemical_list: D000998:Antiviral Agents
references: Lancet. 2014 Nov 22;384(9957):1896-1899
references: 25155413
references: Lancet. 2014 Nov 22;384(9957):1843-1844
references: 25220192
references: Emerg Infect Dis. 2013;19(9):1507-10
references: 23965435
references: Lancet. 2014 Oct 18;384(9952):1423-4
references: 25390318
references: BMJ. 2006 May 27;332(7552):1233
references: 16735322
references: Lancet. 2014 Sep 20;384(9948):e45-6
references: 25247221
references: BMJ. 2011 Aug 16;343:d5268
references: 21846712
references: J Bioeth Inq. 2014 Dec;11(4):417-20
references: 25387576
references: N Engl J Med. 2014 Dec 11;371(24):2249-51
references: 25289888